Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Subcutaneous Bapineuzumab in Mild to Moderate Alzheimer's Disease
NCT00663026Phase 2Completed
- Sponsor
- Pfizer
- Start
- Nov 2008
- Primary completion
- Oct 2010
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of bapineuzumab in Alzheimer's disease (AD) (3 arms), sponsored by Pfizer. Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs). Started Nov 2008; status: completed.
02
Drugs
bapineuzumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00663026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00663026.